Compare Crispr Therapeutics AG (CRSP) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares Core High Dividend ETF — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while iShares Core High Dividend ETF trades at $27.6. The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | HDV | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | — |
52-Week High | $76.78 | $28.09 |
52-Week Low | $44.34 | $23.63 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
HDV (iShares Core High Dividend ETF) trades at $27.93, up 0.83% with a bullish technical signal from moving averages. The ETF focuses on high-quality U.S. dividend stocks with a 3.0% yield, emphasizing defensive sectors like healthcare and energy. Recent performance shows strong total returns with lower volatility than the S&P 500, supported by a 1:5 stock split executed in April 2026.
HDV offers attractive income generation with quality screening, though its concentrated energy exposure (21.56%) introduces sector-specific volatility. The ETF's low expense ratio and defensive positioning provide stability, but investors should monitor oil price sensitivity. Long-term dividend growth potential remains favorable amid current market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
